Table 3: Clinical characteristics of the studied groups.

Number
(%) 		ESBL Producing E. coli Infected Group
(n=49) 		ESBL Non-Producing E. coli Infected Group
(n=39) 		P*- Value Carbapenemase Producing E. coli Infected Group
(n=30) 		Carbapenemase Non-Producing E. coli Infected Group
(n=58) 		P*- Value
Suspected places of infection
NICU
PICU
Surgical ICU 		39 (44.3)
21 (23.9)
28 (31.8)		 18
13
18		 21
8
10		 0.272 14
6
10		 25
15
18		 0.829
CVC inserted 46 (52.3) 28 18 0.305 30 16 0.886
Urinary catheter inserted 28 (31.8) 15 13 0.785 22 6 0.087
ETT inserted 53 (60.2) 31 22 0.514 36 17 0.624
BSI type
Primary
Secondary 		76 (86.4)
12 (13.6)		 41
8		 35
4		 0.41 25
5		 51
7		 0.551
Duration of ICU admission (days) 18.94+4.56 11.67+4.34 0.001** 19.43+4.64 13.79+5.33 0.001**
Patient Survival
Survived
Died 		57
31		 27
22		 30
9		 0.033 24
6		 33
25		 0.032

NICU: Neonatal Intensive Care Unit, PICU: Pediatric Intensive Care Unit, ICU: Intensive Care Unit, CVC: Central Venous catheter, ESBL: Extended Spectrum B-Lactamase, ETT: Endo-Tracheal Tube, ICU; Intensive Care Unit.
Chi-Square test, ** Independent sample t-test